License Agreement Novartis

Molecular Partners AG, a clinical-stage biotechnology company developing a new class of custom anti® drugs, known as DARPin®-Therapeutics, and Novartis AG, announced that they have entered into an option and licensing agreement to cooperate in the development, production and commercialization of the anti-COVID-19 DARPin program® of Molecular Partners. The clinical candidate was jointly developed by Merck and Ablynx in 2011 as part of a joint discovery and development agreement, then developed exclusively by Merck until the Out licensing agreement with Novartis. The agreement also covers the costs associated with the ongoing Phase II-IGUANA clinical trial and a Phase I study to assess the safety and efficacy of the MOR106 subcutaneous study. Novartis does not file or apply patents in least developed countries (LDCs), low-income countries (CCIs) or more than 80% of low-middle income countries (LMIC). In the small number of remaining LMICs in which we submit patents, we want to limit patent applications to patent applications that cover new molecules or chemical units. In addition, we are committed to granting non-exclusive licenses to qualified third parties for the delivery of our patented products exclusively to LDCs or DES. As part of the agreement, Merck will license Novartis for further evaluation in osteoarthritis patients. Under the new agreement, which includes development and commercialization, the partners will work to significantly expand MOR106`s existing development plan for the treatment of atopic dermatitis. The agreement is still subject to approval by U.S. antitrust authorities. As part of the agreement, Novartis has an option to license certain drugs and agrees to pay a down payment of CHF 20 million.

Novartis Pharma has signed an exclusive global licensing agreement for the atopic candidate for dermatitis, MOR106, which is jointly developed by MorphoSys and Galapagos. Germany`s Merck KGaA has entered into a licensing agreement with Novartis to develop a clinical stage program for osteoarthritis. Under an agreement signed by Galapagos and Morphos in 2008, companies will also share these payments. The agreement includes Phase II loan M6495, an anti-ADAMTS5 nanobody that is a potential modification drug for osteoarthritis disease. Novartis has signed a cooperation and licensing agreement with Pliant Therapeutics for the development and commercialization of PLN-1474 preclinical heritage, designed to inhibit `V`1 integrin. The agreement also achieves exclusive global licenses for up to three additional integration objectives. . Merck has already completed two Phase I studies with M6495- one of the healthy subjects showed safety and tolerance, as well as a significant reduction in ARGS (a neoepitop found in synovial fluid and serum in osteoarthritis patients). In 2018, the World Intellectual Property Organization and the International Federation of Pharmaceutical Manufacturers and Associations launched the Drug Patent Information Initiative (Pat-INFORMED). Pat-INFORMED, of which we are founding members, is a unique online public resource that was created to provide basic patent information for participating companies` medicines. Novartis has listed patent information for all our small molecular drugs in the Pat-INFORMED database, which goes well beyond the program`s short-term goal of collecting drug information from a small group of disease zones.

Pliant is already developing PlN-1474 through Phase 1 studies and Novartis will now be responsible for future development, manufacturing and marketing. Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of new therapies for the treatment of fibrosis.